Alzheimer’s disease is a debilitating neurodegenerative disease and the most common form of dementia. Symptoms include irritability, confusion, mood swings, language difficulties and memory loss. Cognitive dysfunction becomes more pronounced as the disease progresses, leading to the loss of bodily functions and eventually death.
Alzheimer’s disease is characterized by the presence of amyloid plaques in the brain. Soluble beta-amyloid (Abeta) oligomers are thought to underlie the cognitive deficits associated with Alzheimer’s disease. Cognition Therapeutics therapies pharmacologically compete with Abeta oligomers for critical receptor targets preventing synapse loss and improving memory and their small molecule therapeutics act through molecular targets that have not been previously implicated in Alzheimer’s disease.
Cognition Therapeutics has received a US patent that describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Disease-relevant screening technologyclosely models the pathology of neurodegenerative diseases and novel, high-quality CNS-biased chemical libraries. These platforms can predict behavioral efficacy of candidate drugs in Alzheimer's models. U.S. National Stage Application: No. 13/263,162, entitled "Inhibitors of Cognitive Decline" was filed on October 6, 2011.
CogRx CEO Hank Safferstein said, "The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- The Strange Organic Molecules In Titan's Atmosphere
- Researchers Created A Laser Bullet To See What It Would Look Like - And Here It Is
- Will Holding Thermal Printer Paper Really Send Your BPA Levels Soaring?
- The Quote Of The Week - Shocked And Disappointed
- As The Weather Changes, So Do Beliefs About Climate Change
- ECFA Workshop: Planning For The High Luminosity LHC
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- "Any more than 100,000 per year of highly qualified immigrants (authorized, unauthorized, overstays..."
- "Regardless of the merits of the research, just because it's published in PLoS ONE doesn't mean..."
- "Hi Nury, good to see you back here again after so many months away from this monster Science20..."
- "The OSX versions are all free, the all in one IOS version is not free. The developer (which I am..."
- "Anonymous, when you disagree, be civil and cite the specific sentence or quote that you disagree..."
- Coffee grounds turned biofuel can heat your home
- Bill and Melinda Gates on GMOs: ‘Poor farmers should not be denied choice of life-saving tools’
- Why do foodies love organics? Because they taste like McDonald’s!
- GMO milk? An enviros dream innovation that most enviros oppose
- National Wildlife Refuge System bans on GMOs and neonics lack transparency, scientific rationale
- Want better sperm? Eat more pesticides
- New policymaking tool for shift to renewable energy
- Teens whose parents exert more psychological control have trouble with closeness, independence
- Two days later: Adolescents' conflicts with family spill over to school, vice versa
- Children in high-quality early childhood education are buffered from changes in family income
- 'Breath test' shows promise for diagnosing fungal pneumonia